Salute e Benessere
Navamedic ASA: Financial report for the 2nd quarter and first half of 2025
"Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen , CEO of Navamedic.
"We are also pleased to announce approval of the medical device OraFID® as primary package for Flexilev®, our medical treatment for Parkinson disease, enabling personalized, fine-tuned treatment with minitablets," she added.
During the second quarter, the (up 23.5 per cent YoY) business area delivered strong growth. and were down 2.8 and 3.5 per cent YoY respectively in the period.
As part of the Prescription Drugs (RX) area, revenues of delivered strong revenues in the period and is up 101.0% YoY. , the company's unique treatment for Parkinson's disease, delivered sales growth of 4.8 per cent YoY. revenues were lower than last year by 12% YTD, while variable between the quarters (-26.6% YoY).
For the area, recent tender wins drove sales growth in the portfolio, which is up 48.4 per cent YoY, whilst the portfolio showed 3.3.% growth.
The company's third business area, , delivered mixed results (-3.5%). Revenues of were slightly down (-1.1%), whilst saw a 10.7 per cent increase in revenues.
Operating results (EBIT) for the second quarter of 2025 amounted to NOK 6.3 million , compared to NOK 6.2 million in 2024, excluding milestone license fee. Operating costs ended at NOK 41.1 million , compared to NOK 39.4 million last year. Net financial items ended at negative NOK 8.1 million and profit before tax was negative NOK 1.5 million .
Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company.
"The past six months have been marked by execution across multiple fronts, from product and company acquisitions to successful launches and impactful marketing initiatives. Several initiatives, such as the dne pharma acquisition, will take time to translate into our growth results but with a solid foundation and continued operational progress, we are well-positioned to realize our ambition of reaching NOK 1 billion in revenue," Andreassen concluded.
Navamedic will present the results for the second quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo . It will be webcast at the following link:
https://navamedic.com/investors/financial-results/
Kathrine Gamborg Andreassen , CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/navamedic-asa/r/navamedic-asa--financial-report-for-the-2nd-quarter-and-first-half-of-2025,c4217794
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-financial-report-for-the-2nd-quarter-and-first-half-of-2025-302529842.html